IL145526A - Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl - Google Patents

Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl Download PDF

Info

Publication number
IL145526A
IL145526A IL145526A IL14552601A IL145526A IL 145526 A IL145526 A IL 145526A IL 145526 A IL145526 A IL 145526A IL 14552601 A IL14552601 A IL 14552601A IL 145526 A IL145526 A IL 145526A
Authority
IL
Israel
Prior art keywords
hdl
enzymotic
lipg
predispositions
vldl
Prior art date
Application number
IL145526A
Original Assignee
Univ Pennsylvania
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/277,401 external-priority patent/US7008776B1/en
Application filed by Univ Pennsylvania, Aventis Pharma Inc filed Critical Univ Pennsylvania
Publication of IL145526A publication Critical patent/IL145526A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL145526A 1999-03-26 2001-09-20 Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl IL145526A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/277,401 US7008776B1 (en) 1996-12-06 1999-03-26 Compositions and methods for effecting the levels of high density lipoprotein (HDL) cholesterol and apolipoprotein AI very low density lipoprotein (VLDL) cholesterol and low density lipoprotein (LDL) cholesterol
PCT/US2000/007870 WO2000057837A2 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of cholesterol

Publications (1)

Publication Number Publication Date
IL145526A true IL145526A (en) 2010-11-30

Family

ID=23060703

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14552600A IL145526A0 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol
IL145526A IL145526A (en) 1999-03-26 2001-09-20 Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL14552600A IL145526A0 (en) 1999-03-26 2000-03-24 Compositions and methods for effecting the levels of high density lipoprotein (hdl) chloesterol and apolipoprotein ai, very low density lipopritein (vldl) cholesterol and low density lipoprotein (ldl) cholesterol

Country Status (13)

Country Link
EP (1) EP1171078A4 (en)
JP (1) JP2002540127A (en)
KR (2) KR20050044812A (en)
AU (1) AU776684B2 (en)
BR (1) BR0009333A (en)
CA (1) CA2363486C (en)
HK (1) HK1043309A1 (en)
IL (2) IL145526A0 (en)
MX (1) MXPA01009727A (en)
NO (2) NO331779B1 (en)
NZ (2) NZ531180A (en)
WO (1) WO2000057837A2 (en)
ZA (1) ZA200107598B (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507808B2 (en) * 2002-12-12 2009-03-24 Isis Pharmaceuticals, Inc. Modulation of endothelial lipase expression
EP1976567B1 (en) 2005-12-28 2020-05-13 The Scripps Research Institute Natural antisense and non-coding rna transcripts as drug targets
US8921329B2 (en) 2008-12-04 2014-12-30 Curna, Inc. Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
US8927511B2 (en) 2008-12-04 2015-01-06 Curna, Inc. Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
DK2396038T3 (en) 2009-02-12 2016-02-01 Curna Inc TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
EP2408919B1 (en) 2009-03-16 2017-10-18 CuRNA, Inc. Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
EP2408920B1 (en) 2009-03-17 2017-03-08 CuRNA, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
WO2010129799A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2010129861A2 (en) 2009-05-08 2010-11-11 Curna, Inc. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
WO2010135695A2 (en) 2009-05-22 2010-11-25 Curna, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
KR101702689B1 (en) 2009-06-16 2017-02-06 큐알엔에이, 인크. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
EP2443237B1 (en) 2009-06-16 2017-02-22 CuRNA, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2446037B1 (en) 2009-06-26 2016-04-20 CuRNA, Inc. Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US20120252869A1 (en) 2009-07-24 2012-10-04 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
CA2770104C (en) 2009-08-11 2019-03-19 Opko Curna, Llc Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
JP5943836B2 (en) 2009-08-21 2016-07-05 カッパーアールエヌエー，インコーポレイテッド Treatment of CHIP-related diseases by inhibition of natural antisense transcripts on 'HSP70 interacting protein C-terminus' (CHIP)
CA2771172C (en) 2009-08-25 2021-11-30 Opko Curna, Llc Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
NO2480669T3 (en) 2009-09-25 2018-04-07
JP6025567B2 (en) 2009-12-16 2016-11-16 カッパーアールエヌエー，インコーポレイテッド Treatment of MBTPS1-related diseases by inhibition of the natural antisense transcript against the membrane-bound transcription factor peptidase, site 1 (MBTPS1)
JP6031356B2 (en) 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2.
EP2516648B1 (en) 2009-12-23 2017-11-08 CuRNA, Inc. Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
CA2785173A1 (en) 2009-12-29 2011-07-28 Curna, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
KR101853508B1 (en) 2009-12-29 2018-06-20 큐알엔에이, 인크. TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
CN102791862B (en) 2009-12-31 2017-04-05 库尔纳公司 IRS2 relevant diseases are treated by suppressing the natural antisense transcript of insulin receptor substrate2 (IRS2) and transcription factor E3 (TFE3)
NO2521784T3 (en) 2010-01-04 2018-05-05
CN102822342B (en) 2010-01-06 2017-05-10 库尔纳公司 Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
US8946182B2 (en) 2010-01-25 2015-02-03 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
EP2539452B1 (en) 2010-02-22 2016-07-27 CuRNA, Inc. Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
KR101877065B1 (en) 2010-04-02 2018-07-10 큐알엔에이, 인크. Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
RU2610661C2 (en) 2010-04-09 2017-02-14 Курна, Инк. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
JP2013525483A (en) 2010-05-03 2013-06-20 カッパーアールエヌエー，インコーポレイテッド Treatment of sirtuin (SIRT) related diseases by inhibition of natural antisense transcripts against sirtuin (SIRT)
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
WO2011150007A2 (en) 2010-05-26 2011-12-01 Opko Curna Llc Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
RU2588654C2 (en) 2010-06-23 2016-07-10 Курна, Инк. Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna
EP2593547B1 (en) 2010-07-14 2017-11-15 CuRNA, Inc. Treatment of discs large homolog (dlg) related diseases by inhibition of natural antisense transcript to dlg
CN103210086B (en) 2010-10-06 2017-06-09 库尔纳公司 NEU4 relevant diseases are treated by suppressing the natural antisense transcript of sialidase 4 (NEU4)
CN103180445B (en) 2010-10-22 2018-02-16 库尔纳公司 IDUA relevant diseases are treated by suppressing the natural antisense transcript of α L iduronases (IDUA)
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
JP6071893B2 (en) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Treatment of NANOG-related diseases by inhibition of natural antisense transcripts to NANOG
CN103620036B (en) 2011-06-09 2016-12-21 库尔纳公司 FXN relevant disease is treated by the natural antisense transcript of suppression Frataxin (FXN)
CN103874486A (en) 2011-09-06 2014-06-18 库尔纳公司 Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules
TR201815503T4 (en) 2012-03-15 2018-11-21 Curna Inc Treatment of brain-mediated neurotrophic factor (bknf) related diseases by inhibition of the native antisense transcript to bknf.
CN102628060A (en) * 2012-03-22 2012-08-08 北京济福霖生物技术有限公司 Production method of low-fat milk
JP6362268B2 (en) 2012-11-05 2018-07-25 塩野義製薬株式会社 Method for evaluating drug efficacy and screening method for EL activity inhibitory substance having therapeutic or preventive effect on diseases associated with EL activity
BR112015022009A2 (en) 2013-03-14 2017-08-29 Shionogi & Co MONOCLONAL ANTIBODY, INHIBITING THE ENZYME ACTIVITY OF VASCULAR ENDOTHELIAL LIPASE
TWI688575B (en) 2014-09-11 2020-03-21 日商塩野義製藥股份有限公司 Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
JPWO2023008337A1 (en) * 2021-07-26 2023-02-02

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU679525B2 (en) * 1992-12-04 1997-07-03 Innovir Laboratories, Inc. Regulatable nucleic acid therapeutic and methods of use thereof
DE69732789T2 (en) * 1996-12-06 2005-08-11 Aventis Pharmaceuticals Inc. HUMAN LIPASE-LIKE GENE GENE-CODED POLYPEPTIDES, AND COMPOSITIONS AND METHODS
AU1941899A (en) * 1997-12-19 1999-07-12 Progenitor, Inc. A lipase expressed in endothelial cells and methods for its use

Also Published As

Publication number Publication date
ZA200107598B (en) 2003-05-28
NO331779B1 (en) 2012-03-26
HK1043309A1 (en) 2002-09-13
NZ531180A (en) 2005-06-24
CA2363486A1 (en) 2000-10-05
CA2363486C (en) 2012-12-18
KR20020029651A (en) 2002-04-19
MXPA01009727A (en) 2002-07-22
NO20014657L (en) 2001-11-21
EP1171078A4 (en) 2002-11-06
BR0009333A (en) 2002-01-08
KR20050044812A (en) 2005-05-12
NO20014657D0 (en) 2001-09-25
IL145526A0 (en) 2002-06-30
NO20100214L (en) 2001-11-21
NZ514350A (en) 2004-12-24
KR100887164B1 (en) 2009-03-10
WO2000057837A2 (en) 2000-10-05
AU3918700A (en) 2000-10-16
WO2000057837A8 (en) 2001-09-27
NO331784B1 (en) 2012-03-26
WO2000057837A3 (en) 2001-01-25
EP1171078A2 (en) 2002-01-16
WO2000057837A9 (en) 2001-10-18
JP2002540127A (en) 2002-11-26
AU776684B2 (en) 2004-09-16

Similar Documents

Publication Publication Date Title
IL145526A (en) Method for diagnosing predispositions to low hdl cholesterol and apolipoprotein ai and method for determining inhibition of enzymotic reaction between lipg and hdl or vldl or ldl
ZA95976B (en) Methods of use for inhibiting bone loss and lowering serum cholesterol
PL343269A1 (en) Alpha-ketoamide inhibitors of 20s proteasome
IL137719A0 (en) Inhibitors of phospholipase enzymes
IL137718A0 (en) Inhibitors of phospholipase enzymes
EP1150118A4 (en) Cholesterol sensor and method for determining cholesterol
AU5869000A (en) System and method for performing context switching and rescheduling of a processor
AU2913701A (en) System and method for facilitating selection of benefits
NO20013161L (en) Preparations of ileum-bile acid transport inhibitors and cholesterol ester transfer protein inhibitors for cardiovascular indications
AU7861800A (en) Method for determining total cost of ownership
AU1856997A (en) Method for raising hdl cholesterol levels
EP1212065A4 (en) Compositions and methods for raising hdl cholesterol levels
IL140989A0 (en) Compositions and methods for treating osteoporosis and lowering cholesterol
AU4955496A (en) Method for determination of cholesterol in low-density lipoprotein or very low-density lipoprotein
AU2002245191A1 (en) Method and system for internet access
AU6737600A (en) System and method for displaying results of search
EP1655037A4 (en) Serum cholesterol lowering agnet or preventive or therapeutic agent for atherosclerosis
EP1149288A4 (en) Process for pan-genomic determination of macromolecular atomic structures
IL132173A0 (en) System for treatment of waste
AU7589598A (en) Elevation of hdl cholesterol by 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
AU3074099A (en) Method and composition for lowering low density lipoprotein cholesterol
AU2768495A (en) Use of 5-alpha-reductase inhibitors to increase hdl cholesterol levels
HUP9900195A3 (en) Fixingelement for fixing of heat-insulating sheets on foonding
AU4387700A (en) System and method of internet access and load management
TW368174U (en) Joining structure for silicon steel sheet set of stabilizator

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees